Cell Reports (Mar 2022)

Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML

  • Gabriela Krivdova,
  • Veronique Voisin,
  • Erwin M. Schoof,
  • Sajid A. Marhon,
  • Alex Murison,
  • Jessica L. McLeod,
  • Martino M. Gabra,
  • Andy G.X. Zeng,
  • Stefan Aigner,
  • Brian A. Yee,
  • Alexander A. Shishkin,
  • Eric L. Van Nostrand,
  • Karin G. Hermans,
  • Aaron C. Trotman-Grant,
  • Nathan Mbong,
  • James A. Kennedy,
  • Olga I. Gan,
  • Elvin Wagenblast,
  • Daniel D. De Carvalho,
  • Leonardo Salmena,
  • Mark D. Minden,
  • Gary D. Bader,
  • Gene W. Yeo,
  • John E. Dick,
  • Eric R. Lechman

Journal volume & issue
Vol. 38, no. 10
p. 110481

Abstract

Read online

Summary: Gene expression profiling and proteome analysis of normal and malignant hematopoietic stem cells (HSCs) point to shared core stemness properties. However, discordance between mRNA and protein signatures highlights an important role for post-transcriptional regulation by microRNAs (miRNAs) in governing this critical nexus. Here, we identify miR-130a as a regulator of HSC self-renewal and differentiation. Enforced expression of miR-130a impairs B lymphoid differentiation and expands long-term HSCs. Integration of protein mass spectrometry and chimeric AGO2 crosslinking and immunoprecipitation (CLIP) identifies TBL1XR1 as a primary miR-130a target, whose loss of function phenocopies miR-130a overexpression. Moreover, we report that miR-130a is highly expressed in t(8;21) acute myeloid leukemia (AML), where it is critical for maintaining the oncogenic molecular program mediated by the AML1-ETO complex. Our study establishes that identification of the comprehensive miRNA targetome within primary cells enables discovery of genes and molecular networks underpinning stemness properties of normal and leukemic cells.

Keywords